Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults
This study examines how taking D-mannose tablets for 2 weeks affects how the body processes dabigatran, a blood thinner medication. Researchers want to understand if D-mannose changes the way dabigatran is absorbed and processed in healthy adults.
Key Objective: This trial tests whether D-mannose affects how the body handles dabigatran, which could help doctors better understand potential drug interactions.
Who to Consider: Healthy adults interested in contributing to research on how natural supplements may interact with blood thinner medications should consider enrolling.
Trial Parameters
Brief Summary
The aim of this study is to investigate the effects of oral D-mannose tablets for 2 consecutive weeks on the pharmacokinetics of dabigatrun etexilate, a P-glycoprotein probe substrate drug, in healthy adults
Eligibility Criteria
Inclusion Criteria: 1. With full capacity for civil conduct, the age of healthy male subjects is ≥18 years old and ≤45 years old 2. Male weight ≥50 kg; body mass index (BMI) within the range of 19.0\~27.0 (including upper and lower limits) 3. Creatinine clearance rate (CRCL: calculated by Cock croft-Gault equation, adult healthy subjects should have CRCL≥90mL/min Exclusion Criteria: 1. History of fainting of needles and blood. 2. Diseases affecting intestinal P-glycoprotein: severe diarrhea (excretion more than 3 times a day with watery stool characteristics), Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulitis, difficult Identify Clostridium infection (recurrent) or Helicobacter pylori infection. 3. Diabetes mellitus; Impaired fasting glucose (IFG); Impaired glucose tolerance (IGT); Oral hypoglycemic agents (including the use of hypoglycemic agents for weight loss purposes). 4. Diseases or conditions with significant risk of major bleeding, such as current or